Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 9Recruiting 8Completed 4Terminated 2Withdrawn 1Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 5Triple Negative Breast Neoplasms 2Sarcoma 2Prostatic Neoplasms 2Breast Neoplasms 2Uveal Melanoma 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Platinum-Refractory Fallopian Tube Carcinoma 1Pancreatic Neoplasms 1Neoplasms 1Melanoma 1Lymphoma 1Liposarcoma 1Fallopian Tube Neoplasms 1Carcinoma, Squamous Cell 1Anatomic Stage III Breast Cancer AJCC v8 1

Interventions

Carboplatin 5niraparib 2Taxes 2Paclitaxel 2Gemcitabine 2Cyclophosphamide 2Bevacizumab 2talazoparib 1sargramostim 1palbociclib 1oregovomab 1olaparib 1epacadostat 1dostarlimab 1birinapant 1atezolizumab 1aldesleukin 1Specimen Handling 1Sirolimus 1Selenium 1Polymerase Chain Reaction 1N-(5-(2,3-dihydrobenzofuryl)sulfonyl)-N'-(3,4-dichlorophenyl)urea 1Metformin 1Magnetic Resonance Spectroscopy 1Letrozole 1Injections 1Hyperthermic Intraperitoneal Chemotherapy 1Gene Expression Profiling 1Fulvestrant 1Colony-Stimulating Factors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Fallopian Tube Neoplasms × olaparib × Clear all
NCT01661868 2012-08-21

Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer

Dana-Farber Cancer Institute

Phase 2 Withdrawn
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡